Analysis of SMAD4 Gene Promoter Methylation in Pancreatic and Endometrial Cancers

  • Aleksandra Nikolić Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
  • Filip Opinćal Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
  • Momčilo Ristanović Institute of Human Genetics, Medical Faculty, University of Belgrade
  • Jovanka Trifunović Institute of Human Genetics, Medical Faculty, University of Belgrade
  • Srbislav Knežević First Surgical Clinic, Clinical Center of Serbia, Medical Faculty, University of Belgrade
  • Dragica Radojković Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
Keywords: endometrial cancer, pancreatic cancer, Methylation,

Abstract


Background. Promoter hypermethylation of the SMAD4 gene has been registered in some cancer types, but in general doesn’t appear to be a frequent event in carcinogenesis. However, only a few published studies deal with this topic and not many cancer types have been analyzed. The aim of this study was to establish SMAD4 gene promoter methylation status in pancreatic and endometrial cancers.

Methods. Patients included in the study (62 subjects) were diagnosed and surgically treated at the Clinical Center of Serbia, University of Belgrade. Patients with pancreatic carcinoma (17 subjects) underwent surgical removal of the pancreatic adenocarcinoma at the First Surgical Clinic, while the patients with endometrial carcinoma (45 subjects) underwent hysterectomy with adnexectomy at the Institute for Gynecology and Obstetrics. Extraction of DNA from fresh tissue samples was performed and the methylation status of the SMAD4 gene promoter was studied by a previously designed PCR-based HpaII and MspI restriction enzyme assay. The resulting PCR products were analyzed by electrophoresis in 2% agarose gels.

Results. Neither of the analyzed samples was found to be hypermethylated.

Conclusion. This is the first report on SMAD4 methylation status in pancreatic and endometrial tumor specimens, and supports the viewpoint that SMAD4 hypermethylation is not a common event in malignant tumors. Nevertheless, promoter hypermethylation remains a candidate mechanism for SMAD4 inactivation in malignant tissue as a potential cause of decreased or lost SMAD4 expression in certain tumor types, and should be further investigated in different tumor types and larger cohorts of patients.

Author Biographies

Aleksandra Nikolić, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
Filip Opinćal, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
Momčilo Ristanović, Institute of Human Genetics, Medical Faculty, University of Belgrade
Jovanka Trifunović, Institute of Human Genetics, Medical Faculty, University of Belgrade
Srbislav Knežević, First Surgical Clinic, Clinical Center of Serbia, Medical Faculty, University of Belgrade
Dragica Radojković, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade

References

Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Molecular Oncology 2007;1(1):26-41. doi: 10.1016/j.molonc.2007.01.004

Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Kern SE. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1. Science 1996;271(5247):350-353. doi: 10.1126/science.271.5247.350

Yang G, Yang X. Smad4-mediated TGF-β signaling in tumorigenesis. International Journal of Biological Sciences 2010;6:1-8. doi: 10.7150/ijbs.6.1

Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and Biophysical Research Communications 2003;306(4):799-804. doi: 10.1016/s0006-291x(03)01066-0

Roth S, Laiho P, Salovaara R, Launonen V, Altonen LA. No SMAD4 hypermethylation in colorectal cancer. British Journal of Cancer 2000;83(8):1015-1019. doi: 10.1054/bjoc.2000.1387

Nikolic A, Ristanovic M, Perovic V, Trifunovic J, Perovic M, Radojkovic D. Genetic Alterations in SMAD4 and K-ras in Serbian Patients With Endometrial Carcinoma. International Journal of Gynecological Cancer 2012;22(3):442-446. doi: 10.1097/igc.0b013e31823fabab

Nikolic A, Kojic S, Knezevic S, Krivokapic Z, Ristanovic M, Radojkovic D. Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats. Cancer Epidemiology 2011;35(3):265-271. doi: 10.1016/j.canep.2010.10.002

Calva D, Dahdaleh FS, Woodfield G, Weigel RJ, Carr JC, Chinnathambi S, Howe JR. Discovery of SMAD4 promoters, transcription factor binding sites and deletions in juvenile polyposis patients. Nucleic Acids Research 2011;39(13):5369-5378. doi: 10.1093/nar/gkr091

Aitchison AA, Veerakumarasivam A, Vias M, Kumar R, Hamdy FC, Neal DE, Mills IG. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. The Prostate 2008;68(6):661-674. doi: 10.1002/pros.20730

Schutte M. DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Annals of Oncology 1999;10(suppl 4):56-59. doi: 10.1093/annonc/10.suppl_4.s56

Zhou Y, Kato H, Shan D, Minami R, Kitazawa S, Matsuda T, Wake N. Involvement of mutations in theDPC4 promoter in endometrial carcinoma development. Molecular Carcinogenesis 1999;25(1):64-72. doi: 10.1002/(sici)1098-2744(199905)25:1<64::aid-mc8>3.0.co;2-z

Nikolic A, Cacev T, Aralica G, Hadzija MP, Kapitanovic S, Radojkovic D. Mononucleotide repeats in the SMAD4 gene promoter in colon carcinoma tissue of Croatian patients. Experimental and Molecular Pathology 2015;98(2):133-135. doi: 10.1016/j.yexmp.2015.02.008

Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y, et al. . Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut 2006;55(6):764-774. doi: 10.1136/gut.2005.076430

Wang LH, Kim SH, Lee JH, Choi YL, Kim YC, Park TS, Shin YK. Inactivation of SMAD4 Tumor Suppressor Gene During Gastric Carcinoma Progression. Clinical Cancer Research 2007;13(1):102-110. doi: 10.1158/1078-0432.ccr-06-1467

Takenaka K, Gemma A, Yoshimura A, Hosoya Y, Nara M, Hosomi Y, et al. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. Mol Med Rep 2009;2: 73-80.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology 2010;17(6):1471-1474. doi: 10.1245/s10434-010-0985-4

Sameer AS, Siddiqi MA. SMAD4 promoter hypermethylation in Kashmiri colorectal cancer cases. Saudi Journal of Gastroenterology 2011;17(4):297. doi: 10.4103/1319-3767.82591

Fotouhi O, Adel FM, Kjellman M, Sulaiman L, Höög A, Zedenius J, Larsson C. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study. Epigenetics 2014;9(7):987-997. doi: 10.4161/epi.28936

Published
2018/02/09
Section
Original Scientific Paper